NowDiagnostics, Springdale, Ark, is working with BARDA, the Biomedical Advanced Research and Development Authority arm of the US Department of Health and Human Services, to develop a serological test for SARS-CoV-2 antibodies that can be used across a variety of healthcare settings—from clinics to hospital emergency rooms—and ultimately by consumers for at-home use. The covid-19 rapid antibody test, using NowDiagnostics’ self-contained AdexUSDx platform, requires no additional materials (reagents and buffers), equipment, processing, or refrigeration. No matter where it is conducted, the AdexUSDx COVID-19 Test is designed to deliver lab-quality results in 15 minutes detecting the presence of SARS-CoV-2 antibodies in individuals who have been exposed to the virus. This can include those who have been recently or previously infected with covid-19, regardless of whether they presented with severe, moderate, mild, or no symptoms. The rapid-results AdexUSDx COVID-19 Test requires only a fingerstick to obtain 40 μL of capillary blood, venous whole blood, serum, or plasma and has the potential to be deployed directly in homes and workplaces. Availability of point-of-care (POC) and over-the-counter (OTC) tests would allow individuals to be screened easily and quickly, yielding test results in minutes instead of days. An application for emergency use authorization was filed with the FDA in May 2020 for moderate complexity use of the AdexUSDx COVID-19 Test. For more information, visit NowDiagnostics. Featured image: The AdexUSDx COVID-19 Test is a rapid serology, self-contained assay that measures the presence of SARS-CoV-2 antibodies to deliver accurate and reliable results in 15 minutes with no buffers, reagents, or additional equipment. (courtesy NowDiagnostics)